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Abstract
Background. Surgical resection is the most effective therapy for liver cancer. Intraoperative blood loss during liver resection
remains a major concern due to association with higher postoperative complications. The InLine radiofrequency ablation
device (ILRFA) has achieved promising results in liver surgery with minimal blood loss and no increase of postoperative
complications. In this multicentre controlled study, 108 patients undergoing liver resection were investigated. Patients and
methods. A total of 108 patients underwent liver resections in 4 medical centres; the prospective sequential cohort study
consisted of 54 ILRFA and 54 ultrasonic surgical aspirator transections as the control group. Results. The type of liver
resection performed was very similar in both groups. The median number of RFA deployments was 3 (range 112) with
a median coagulation time of 9 (range 336) min. Median blood loss was 165920 ml (range 5675) in the ILRFA and
654983 ml (range 803600) in the control group (pB0.001). The median transection time was 27 (2219) min in the
ILRFA group and 35 (562) min in controls. Conclusions. Our study indicates that ILRFA device for liver transection is
effective in reducing blood loss and is safe. Precoagulation before parenchymal transection appears to be a valid concept in
liver surgery. The avoidance of vascular inflow occlusion during parenchymal transection could also be of value.
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Introduction
Surgical resection is the most effective therapy for
selected patients with primary or secondary liver
cancer [1,2]. With improvements in surgical techni-
ques, advanced methods for hepatic transection and
changes in postoperative management, surgical out-
comes have been improved dramatically [35]. It has
been reported that operative mortality and both
overall and disease-free survival rates have improved
over the past two decades [4,5]. However, intraopera-
tive blood loss during liver resection remains a major
concern due to association with higher postoperative
complications [6]. This is especially problematic
in cirrhotic, post chemotherapy and fatty liver
[79]. Multiple techniques and devices have been
used to reduce intraoperative blood loss, such as
the Pringle manoeuvre, total vascular exclusion, ultra-
sonic aspirator and water-jet cutter [1013].
Radiofrequency ablation (RFA) is a relatively new
technique, first used for the ablation of aberrant
conduction pathways in the heart [14]. Application
in liver tumours began in the 1990s, and the
prevalence of RFA has been increasing rapidly be-
cause of its efficacy, safety and versatility [15].
Habib’s group first described RFA-assisted liver
resection; they used a monopolar RFA device to
pre-coagulate liver before parenchymal transection
and achieved significant reduction of blood loss
(30910 ml) in 15 patients [16]. Recently, Morris
and Daniel developed a novel bipolar multi-array
RFA device  the InLine RFA device (ILRFA; Resect
Medical, Fremont, CA, USA), which has achieved
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promising results in liver surgery with minimal blood
loss and no increase of postoperative complications
[17], but the clinical trials to date have been small in
size. We designed this multicentre study to evaluate
the effectiveness of ILRFA for the reduction of blood
loss during liver transection in 108 patients, and also
postoperative complications.
Patients and methods
Between November 2003 and November 2006, 108
patients underwent liver resections in 4 medical
centres: St George Hospital (Sydney, Australia);
University Hospital of the Saarland (Homburg,
Germany); University of Hawaii and Kuakini Medical
Center (Hawaii, USA) and Bassett Healthcare
(Cooperstown, USA). The cohort study consisted
of 54 patients who had undergone ILRFA preco-
agulation followed by ultrasonic surgical aspirator
(USA) transection in 4 medical centres (ILRFA
group) and 54 patients who had undergone USA
transection as a control group in the Department of
Surgery, St George Hospital, Sydney, Australia.
These were prospective sequential series at St George
Hospital. The patients’ characteristics are shown in
Table I.
Equipment
The ILRFA device consists of a linear array of six
electrodes, each 4 cm or 6 cm long mounted on a 5
cm long plastic base (Figure 1). The InLine RFA
device is compatible with a range of RFA generators,
in this study the RITA† 1500 Generator (RITA
Medical Systems, Mountain View, CA, USA) was
used for producing power. This machine generates
radiofrequency current at 460 KHz with a maximum
power output of 150 W. The amount of power applied
depended on the depth of resection. Table II shows
the protocol of power settings. The parenchymal
transection was performed with an ultrasonic surgical
aspirator (Selector† Integra NeuroSciences Ltd,
Hampshire, UK).
Surgical procedures
All operations were performed under general anaes-
thesia after mobilization of the liver and intraoperative
ultrasound. The Pringle manoeuvre was only applied
in selected patients to minimize blood loss. During
surgery, the resection plane was marked with dia-
thermy; after RFA is used, the parenchyma is har-
dened and it is more difficult to feel the tumour edge
or see it via ultrasound. We strongly recommend that
intraoperative ultrasound is used before probe place-
ment. This is particularly important when a vascular/
biliary sheath crosses the resection plane which is to
be retained and must be avoided. Then the ILRFA
device was deployed in this marked line, often
requiring several ILRFA placements to completely
treat the resection plane (Figures 2 and 3). Finally, the
liver parenchyma was transected with the USA. In the
control group, only the USA was used for liver
transection.
The volume of intraoperative blood loss was
measured from the sum of the blood aspirated in the
suction bottles and the blood loss as calculated by
sponge weights. The surface area of each resection
plane was then measured to allow calculation of the
blood loss per cm2 of liver transection. The time taken
for transection was also recorded.
Statistical analysis
Statistical analysis was performed with SPSS
for Windows (Version 12.0; SPSS Inc., Chicago,
IL, USA). Student’s t test, x2, MannWhitney
non-parametric test and Fisher’s exact test were
used as appropriate. Data are expressed as mean9
standard deviation. pB0.05 was considered statisti-
cally significant.
Table I. Demographics and preoperative assessment of ILRFA and
control group.
Parameter
ILRFA group
(n54)
Controls
(n54)
Age (years) 63 (3085) 62 (2882)
Gender (M/F) 30/24 31/23
Diagnosis
Colorectal cancer 40 36
Hepatocellular carcinoma 10 7
Cholangiocarcinoma 4 6
Adenoma 0 2
Breast cancer 0 1
Pancreatic cancer 0 1
Gallbladder cancer 0 1
Quality of liver
Post chemotherapy 19 15
Steatosis 20 25
Cirrhosis 5 4
Figure 1. InLine RFA coagulator (ILRFA).
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Results
There was no mortality. The postoperative hospital
stay was 1092 days. The surgical results are shown in
Table III. The type of liver resection was very similar
in both groups, including 14 non-anatomic and 40
anatomic resections (formal lobectomy or extended
resection) in the ILRFA group, 18 non-anatomic and
36 anatomic resections in controls. The median
number of RFA deployments was 3 (range 112)
with a median coagulation time of 9 min (range
336). The transection time in ILRFA was slightly
faster than that in controls: 24 min (range 2219) vs
35 min (range 562), but this difference was not
statistically significant. The mean intraoperative blood
loss was 165920 ml (range 5675) in the ILRFA
group and 654983 ml (range 803600) in the
controls, a 74.8% reduction (pB0.001) (Figure 4).
The mean transection surface area was not different
between the ILRFA and control groups. The mean
transection blood loss per unit resection area
was 3.2990.40 ml/cm2 (range 0.1412.33) in the
ILRFA group compared with 6.4190.71 ml/cm2
(range 0.9236) in controls; the reduction was
48.7% (pB0.001) (Figure 5). In the ILRFA group,
only 6 (11.1%) transections were performed with
a Pringle manoeuvre, whereas in the control group
32 (59.3%) Pringle manoeuvres were required
(pB0.001). Postoperative bile leak occurred in five
patients (9.3%) following ILRFA compared with six
(11.1%) in the control group.
Discussion
Surgical resection offers the best established curative
treatment for patients with hepatocellular carcinoma
or colorectal cancer liver metastases, which can result
in significant long-term survival benefit in 2025% of
patients [18,19]. However, liver surgery is still asso-
ciated with a morbidity rate of 30% and a mortality
rate up to 5% [20,21]. Intraoperative blood loss
remains a significant concern for surgeons operating
on the liver. The mean blood loss has been reported to
be between 600 and 1300 ml [21,22], with 2847%
of the patients requiring blood transfusion [21,23].
Several studies have shown that blood loss correlates
adversely with length of hospital stay, complication
rate and patient survival [24,25]. It also has been
shown that patients requiring more than 10 units of
blood after liver resection for colorectal cancer me-
tastasis have an increased risk of tumour recurrence
and poor survival, probably due to immunosuppres-
sion [26,27].
In this study, a multicentre controlled study was
performed on ILRFA-assisted liver resection. A total
of 108 patients underwent liver resection. The type of
liver resection was very similar in both ILRFA and
control groups, the hospital stay was almost the same,
Table II. Power setting for RITA† 1500 generator.
Electrode
deployment
Initial power
setting (90 s)
Second power
setting (60 s)
Final power
setting (30 s)
1 cm 13 15 17
2 cm 27 30 33
3 cm 41 45 50
4 cm 54 60 66
5 cm 68 75 83
6 cm 77 85 94
Figure 2. ILRFA deployment.
Figure 3. Avascular liver transection plane.
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i.e. 1092 days. The transection time in the ILRFA
group was only slightly faster than that of the controls,
but at least it certainly does not take longer. The mean
transection surface area was not different between the
ILRFA and control groups (p0.05). Intraoperative
blood loss was reduced dramatically in the ILRFA
group, with a 74.8% reduction, and transection blood
loss per unit resection area was also reduced signifi-
cantly with a 48.7% reduction.
ILRFA is a bipolar RFA device which has several
advantages over previous unipolar RFA devices. The
unipolar probe has to be deployed many times to
cover the designed resection plane, which necessarily
makes a slow approach. On the contrary, ILRFA
allows much more rapid (3 min for 651 cm) and
precise treatment. The resection plane then can be
dissected almost bloodlessly with an ultrasonic surgi-
cal aspirator and only a few larger vessels and biliary
ducts need to be ligated. Secondly, the bipolar device
does not require grounding pads, because both elec-
trodes are located on the probe and the alternating cu-
rrent circuit is confined within the target tissue [17].
The ILRFA device has shown promising results in
liver surgery. We have shown that it can achieve
haemostasis in the liver trauma setting [28]. Using
ILRFA we were able to stop bleeding within 8 min
with a 63.88% reduction of blood loss in a simulated
sharp injury animal model. ILRFA may have other
advantages. Vascular inflow occlusion (Pringle man-
oeuvre) is widely used in liver resection, but has been
associated with ischaemia-reperfusion injury. Using
ILRFA vascular inflow occlusion may not be neces-
sary any more. We were also concerned that an excess
of bile leakage might be seen post ILRFA, but this was
not the case. Constant et al. also reported that no
postoperative bile leak occurred in their study using a
RFA sealing device [29]. However, they used a
relatively smaller animal model  swine weighing
2936 kg. In our study, postoperative bile leak did
occur in ILRFA in 5 (9.3%) of 54 patients, but was
not increased compared to the control group with 6
(11.1%) of 54. Finally, the precise 1 cm zone of
coagulative necrosis may allow for a transection plane
that is relatively close to the tumour without jeopar-
dizing radicality.
The surgical resection of cirrhotic liver does in-
crease blood loss compared with normal liver [30].
The hilar dissection is more difficult with the
surrounding fibrous liver and potentially deranged
clotting, and cirrhotic liver is more vulnerable to
ischaemia. Studies have shown that normal liver is
able to tolerate continuous inflow occlusion for over
60 min, and intermittent occlusion for substantially
longer [23,31]. However, cirrhotic liver can only
tolerate ischaemic episodes of approximately 30 min
with increased mortality and morbidity compared
with normal liver [32]. When using ILRFA, surgeons
only required vascular inflow occlusion in 11.1% of
patients.
Table III. Surgical results of ILRFA and control groups.
Parameter
ILRFA group
(n54)
Control group
(n54) p value
Blood loss (ml) 165920 654983 B0.001
Resection time (min) 24 (2219) 35 (562) 0.05
Surface area (cm2) 63.3296.18 103.8796.69 0.05
Blood loss per cm2 (ml/cm2) 3.2990.40 6.4190.71 B0.001
Type of resection
Non-anatomical resection 14 18
Anatomical resection (formal lobectomy or extended resection) 40 36
Pringle manoeuvre 6 32 B0.001
Bile leak 5 (9.3%) 6 (11.1%)
74.8% Reduction
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Figure 4. Comparison of intraoperative blood loss between ILRFA
and control groups.
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Figure 5. Comparison of intraoperative blood loss per cm2 between
ILRFA and control groups.
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We accept that are some limitations to this study.
The patients were not randomly selected; the patients
in the treatment group were based on criteria such as
candidate for liver resection and available equipment.
Also, we investigated the ILRFA group first, because
we needed the data for the ILRFA-treated patients
first. The control group originated from one hospital
during the same period; however, we do not believe
that there is a bias in this study. In conclusion, our
study indicates that the ILRFA device is effective and
safe for liver transection. Precoagulation before par-
enchymal transection appears to be a valid concept in
liver surgery.
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